Fosamax and Osteonecrosis of the Jaw: Medical Literature on Causation and Risk

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy of Health Information and Evolving Risk Communication

The legacy of general health and science information dissemination has long provided a foundation for public understanding of medical risks and therapeutic benefits. Within this broad context, the communication of pharmaceutical safety profiles has been a central concern, particularly as medications transition from clinical trials to widespread use. The historical emphasis on patient education and informed consent has established a framework for discussing adverse events, yet the focus has traditionally remained on the individual patient’s clinical journey. As the volume of post-market surveillance data grows, a natural extension of this heritage involves examining how therapeutic exposures intersect with occupational and environmental settings. This pivot is especially relevant when considering medications that have been associated with rare but serious conditions, where the risk assessment must account for both prescribed use and potential unintended exposure pathways. The shift from a purely clinical perspective to one that includes occupational health considerations requires a careful re-evaluation of exposure thresholds and population-level risk factors. By broadening the lens beyond the doctor-patient relationship, we can better understand how pharmaceutical agents may pose risks not only to those receiving treatment but also to individuals who encounter these substances through their work environment. This transition acknowledges that the legacy of health information must evolve to encompass the full spectrum of exposure scenarios.

Bridging Clinical and Occupational Perspectives on Fosamax

Building on this legacy, the specific case of Fosamax (alendronate) illustrates the need to bridge clinical and occupational perspectives. Fosamax is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its pharmacological action involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a recognized adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. It can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Clinical presentation typically involves pain, swelling, and exposed bone in the jaw, often following dental procedures. Diagnosis relies on clinical examination and imaging, with a focus on ruling out other causes such as malignancy or infection. The condition has been reported in patients taking bisphosphonates, including Fosamax and Fosamax Plus D (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways and Evidence Linking Fosamax to ONJ

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated but are thought to involve bisphosphonate-induced suppression of bone turnover. Bisphosphonates accumulate in bone, particularly in areas of high remodeling such as the jaw, and inhibit osteoclast activity. This can impair the normal repair and remodeling processes, making the jawbone more susceptible to necrosis, especially after trauma or infection. A multiscale characterization of jawbone has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research highlights the unique structural and cellular properties of the jawbone that may predispose it to ONJ under antiresorptive therapy. Risk factors for developing ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Timeline, Risk Quantification, and Causation Considerations

The timeline between exposure to Fosamax and documented harm varies. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the medication, but a subset experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A cohort study among female patients treated for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific warning under Section 5.4 titled "Osteonecrosis of the Jaw," which describes the condition, associated risk factors, and recommendations for management (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Similar warnings are present for Fosamax Plus D (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). These warnings inform healthcare providers and patients about the potential risk, but the adequacy of communication to patients may vary. Causation considerations for affected patients involve establishing a temporal relationship between Fosamax use and ONJ onset, ruling out other causes, and considering the presence of known risk factors. The label notes that ONJ can occur spontaneously and is generally associated with dental procedures or infections, which complicates direct causation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk-benefit profile of Fosamax must be weighed, particularly for low-risk fracture patients, where the optimal duration of use has not been determined, and drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, Fosamax is associated with a rare but serious risk of osteonecrosis of the jaw, with evidence supporting a causal link through bisphosphonate-induced suppression of bone turnover. The risk increases with longer exposure and is influenced by dental procedures and other factors. Warnings in the prescribing information address this risk, but affected patients should consider the timeline of exposure and individual risk factors when evaluating causation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate) is a bisphosphonate medication used to treat and prevent osteoporosis in postmenopausal women, increase bone mass in men with osteoporosis, treat glucocorticoid-induced osteoporosis, and treat Paget's disease of bone. It works by inhibiting bone resorption, thereby increasing bone mass and reducing fracture risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What is osteonecrosis of the jaw (ONJ) and how is it linked to Fosamax?

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the jaw, often presenting with pain and swelling. It is a recognized adverse effect of bisphosphonates like Fosamax, thought to result from suppressed bone turnover, particularly in areas of high remodeling such as the jaw. Risk factors include invasive dental procedures, cancer, concomitant therapies, and poor oral hygiene (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

How common is ONJ in Fosamax users?

ONJ is rare. A cohort study found that the risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use, but absolute risks remained low, approximately 0.05% after 5 years (https://pubmed.ncbi.nlm.nih.gov/39400702/).

What should I do if I have taken Fosamax and develop jaw symptoms?

If you experience jaw pain, swelling, or exposed bone, consult your healthcare provider immediately. They may recommend discontinuing Fosamax, especially before invasive dental procedures, and evaluate for ONJ. The prescribing information advises that discontinuation may reduce risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.